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Abstract 
Targeted gene delivery, transfection efficiency and toxicity concerns remain a challenge for effective gene 
therapy. In this study, we dimerized the HIV-1 TAT peptide and formulated a nanoparticle vector (dTAT 
NP) to leverage the efficiency of this cell penetrating strategy for tumor-targeted gene delivery in the 
setting of intratracheal administration. Expression efficiency for dTAT NP-encapsulated luciferase or 
angiotensin II type 2 receptor (AT2R) plasmid DNA (pDNA) was evaluated in Lewis Lung carcinoma 
(LLC) cells cultured in vitro or in vivo in orthotopic tumor grafts in syngeneic mice. In cell culture, dTAT 
NP was an effective pDNA transfection vector with negligible cytotoxicity. Transfection efficiency was 
further increased by addition of calcium and glucose to dTAT/pDNA NP. In orthotopic tumor grafts, 
immunohistochemical analysis confirmed that dTAT NP successfully delivered pDNA to the tumor, where 
it was expressed primarily in tumor cells along with the bronchial epithelium. Notably, gene expression in 
tumor tissues persisted at least 14 days after intratracheal administration. Moreover, bolus administration 
of dTAT NP-encapsulated AT2R or TRAIL pDNA markedly attenuated tumor growth. Taken together, our 
findings offer a preclinical proof of concept for a novel gene delivery system that offers an effective 
strategy for locally administering lung cancer gene therapy. 
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Introduction 
   Lung cancer is the leading cause of cancer-related morbidity and mortality in the United States, 
although its prognosis has improved due to advances in diagnostic and surgical techniques and early 
surveillance. The American Cancer Society estimates that 221,130 persons in the United States developed 
lung cancer in 2011, with 156,940 deaths (1). Lung cancer-dependent deaths constituted 15% (men) and 
12% (women) of estimated total cancer-related deaths in 2011  (1). From 1995 to 2001, the relative 5-
year survival ratio of patients with lung or bronchus cancer was still quite low (15%), with minimal 
improvement since the 1970’s (12%). Therefore, novel treatment strategies for lung cancer are urgently 
needed. 
   In order to develop successful gene therapy systems, it is essential to improve gene transfection 
efficiency while minimizing toxicity and enhancing stability in vivo (2-7).  Adenoviral vectors are 
effective, as they allow strong transgene expression in a variety of tissues, including tumor tissue (8, 9). 
However, their clinical efficacy is limited because they tend to be rapidly cleared from circulation (10, 11). 
Viral vectors are also potentially pathogenic; cases of viral infection have been reported (12). Therefore, 
nonviral vectors should be more promising as gene delivery vehicles: they are safe, easy to synthesize, 
cost-effective, and have a low degree of immunogenicity compared to viral vectors (13). Because naked 
plasmid DNA (pDNA) does not easily penetrate cellular membranes (14), nonviral gene delivery systems 
may include agents to improve intracellular delivery and promote transfection; pDNA complexed with 
cationic lipids (lipoplexes) and polymers (polyplexes) are the most commonly employed nonviral gene 
delivery vehicles (15-21). 
   The HIV-1 TAT peptide, which represents a protein transduction domain (22, 23) and a nuclear 
localization sequence (24), has been reported to show unusual translocation abilities by directly crossing 
biological membranes independent of receptors and temperature (25).  The TAT peptide has been 
suggested to be an effective vector offering potential for translatable gene delivery;  TAT-Ca/pDNA 
complexes were stable, maintaining particle size and transfection efficiency even in the presence of 10% 
of FBS (26) .   
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   Angiotensin II (Ang II), an octapeptide hormone, is the key effector in the renin-angiotensin system.  
Ang II has two well-defined receptors: Ang II type 1 and type 2 receptors (AT2R) (27).   AT2R, the 
second major receptor isoform, is primarily expressed in the mesenchyme of the fetus and to a limited 
extent in adult tissues (28). AT2R is known to inhibit cell proliferation and stimulate apoptosis in 
cardiovascular and neuronal tissues in vitro (29). Our previous studies revealed that AT2R deficiency 
significantly altered chemical carcinogen-induced tumorigenesis in mouse colon (30) and lung (31).  A 
recent study indicates that host AT2R deficiency stimulates the growth of murine pancreatic carcinoma 
grafts (32). These results suggest that AT2R expression plays an important role in tumor growth.  
   Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a naturally occurring cytokine that 
acts by binding as a homotrimer to Death Receptor (DR)-4 or -5 and recruiting an adaptor receptor, such 
as FADD or caspase-8.  Since activated caspase-8, in turn, activates a caspase pathway that induces 
extrinsic apoptotic cell death (33), TRAIL is known to be a strong anti-cancer gene candidate (34).  In 
fact, TRAIL gene therapy has been tested in multiple mouse cancer models with success (35, 36). 
Targeted gene delivery to cancer tissue should reduce side effects in healthy tissue and enable TRAIL as a 
candidate gene for gene therapy. 
   In the present study, we have developed a modified TAT peptide by connecting two TAT peptides in 
tandem (dTAT). Here we show that dTAT NP incorporating luciferase or AT2R pDNA (dTAT/pLUC or 
dTAT/pAT2R) administered via intratracheal spray can be detected primarily in the tumor tissues of the 
lung and in bronchial epithelium. Bolus administration of dTAT/pAT2R or of dTAT/pTRAIL, which was 
used as a positive control for the apoptosis inducer, significantly attenuated the growth of lung carcinoma 
grafts in syngeneic mice.  Therefore, dTAT NP are a realistic gene delivery system, and the dTAT and an 
apoptosis inducer gene NP can be used as a powerful and less toxic therapeutic for lung cancer. 
Materials and methods 
Materials 
 Plasmid DNA (pDNA) encoding human AT2R (agtr2 pcDNA3.1+) was obtained from the UMR cDNA 
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Resource Center (University of Missouri-Rolla). The pDNA encoding human TRAIL (trail pCMV-
SPORTS 6) was purchased from Open Biosystems. Firefly luciferase pGL3 (pLUC) and pcDNA3.1+ 
were from Promega and Invitrogen, respectively. The dTAT peptide was purchased from Biomatik Corp.. 
Branched polyethylenimine (PEI, 25 kDa) was obtained from Aldrich . Lewis Lung Carcinoma (LLC, 
CRL-1642), A549 (CCL-185), and BEAS-2B (CRL-9609) cells were from the American Type Culture 
Collection. These cells were not specifically characterized for this study. Dulbecco’s Modified Eagle’s 
Medium (DMEM) and Ham’s F-12 medium were from Fisher Scientic. Fetal bovine serum (FBS) was 
purchased from Equitech-bio, Inc.. Penicillin-streptomycin and trypsin-EDTA were from Invitrogen. MTS 
reagent [tetrazolium compound; 3-(45-dimethylthiazol-2-yl)-5- (3-carboxymethoxyphenyl) -2-(4-
sulfophenyl)-2H-tetrazolium, inner salt] was from Promega.  Other chemicals were analytical grade. 
 
Cell culture 
 LLC,A549, and BEAS-2B cells were grown in DMEM, Ham’s F-12 medium, and BEBM media 
(BEGM kit, Lonza), respectively, supplemented with 10% v/v FBS and 1% v/v penicillin/streptomycin at 
37º C in a humidified air atmosphere containing 5% CO2.  
 
Preparation of dTAT/pDNA NP  
 The dTAT/pDNA NP were prepared by mixing via pipette 10 µL pDNA (0.1 µg pDNA/µL) and 15 µL 
dTAT (1 µg dTAT/µL) solutions. The resultant dTAT/pDNA solution was stabilized by adding either 25 
µL of 10% glucose, 0.2M NaCl, or 0.2M KCl solution for in vitro studies. For in vivo mouse studies, 25 
µL of 10% glucose was added to the dTAT/pDNA solution. Finally, 15 µL 0.3M CaCl2 was added to the 
stabilized solution. The final solution was mixed vigorously by pipette.  Before use, dTAT/pDNA NP 
were allowed to equilibrate for 20 min at 4º C.  
 
Preparation of PEI/pDNA NP 
 PEI/pLUC NP were prepared by adding 10 µl pGL3 solution (0.1 µg/µL) to 15 µL PEI solution (N/P 
ratio 10) while pipetting, followed by 20 min incubation at 4º C. The N/P ratio refers to the molar ratio of 
7 
 
amine groups in the cationic polymer, which represent the positive charges, to phosphate groups in the 
plasmid DNA, which represent the negative charges. NP were prepared immediately prior to each 
individual experiment. 
 
In vitro cell transfection studies 
 LLC cells were trypsinized, counted, and diluted to a concentration of approximately 80,000 cells/mL. 
Then 0.1 mL of that dilution was added to each well of a 96-well plate, and the cells were incubated in a 
humidified atmosphere at 5% CO2 at 37°C for 24 h. Immediately before transfection, cells were washed 
once with PBS and 100 µl sample (20% of NP to 80% of serum free cell culture medium) was added to 
each well. Cells were incubated with the NP for 5 h. The transfection agent was then aspirated and 100 µL 
of fresh serum-containing medium was added, followed by further incubation. Luciferase expression was 
determined at 24 h after transfection by the Luciferase Assay System from Promega according to the 
manufacturer’s recommended protocol. The light units were normalized against protein concentration in 
the cell extracts, which was measured using the BCA™ Protein Assay (Thermo Scientific). Transfection 
results were expressed as relative light units (RLU) per mg of cellular protein.  
 
Assessment of cytotoxicity (MTS Assay) 
 Cytotoxicity of polymers was determined by the CellTiter 96® Aqueous Cell Proliferation Assay 
(Promega). LLC cells were grown as described in the transfection experiments. Cells were treated with 
the samples for ~24 h. The medium was then removed and replaced with a mixture of 100 µL fresh 
culture medium and 20 µL MTS reagent solution. The cells were incubated for 3 h at 37°C in the 5% CO2 
incubator. The absorbance of each well was measured at 490 nm using a microtiter plate reader 
(SpectraMax, M25, Molecular Devices Corp.) to determine cell viability. 
 
Cell viability analysis 
 The MTT assay was performed to examine the effect on LLC cell proliferation in vitro of dTAT/pAT2R 
or of high concentration glucose, NaCl, or KCl in the dTAT/pDNA solution. In brief, 700 LLC cells were 
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seeded in 96 well plates 24 h prior to the addition of dTAT/pAT2R, glucose, or salt solution.  The cancer 
cells were treated with dTAT/pAT2R alone, dTAT/pAT2R with additional glucose or salt solution, or 
glucose or salt solution alone in serum free-DMEM (0.25 or 0.5g of dTAT/pDNA per well) at 37°C for 5 
h, and then the medium was replaced with DMEM containing 10% FBS. After 48h incubation at 37°C, 
the MTT assay was carried out as previously described (37). The same procedure was used to examine the 
potential adverse effect of dTAT alone (1.87 or 3.74 g dTAT/mL) on the viability of LLC, A549, and 
BEAS-2B cells.  In this study, the MTT assay was carried out after 1, 3, or 5 days incubation in serum-
containing DMEM or BEBM medium. 
 
Gene expression analysis using real-time PCR 
 Transfection of pAT2R into LLC cells was confirmed by real-time PCR. 5000 LLC cells were seeded in 
24 well plates 24 h prior to the addition of dTAT/pAT2R.  The cancer cells were treated with 
dTAT/pAT2R in serum free-DMEM (1 or 2g of dTAT/pDNA per well) at 37°C for 5 h and then were 
allowed to grow in DMEM containing 10% FBS at 37°C for 48 h. Then, gene expression was analyzed as 
previously described (37). AT2R primers were 5’ –ACTTCGGGCTTGTGAACATC-3’ (forward), and 5’ 
–TAAATCAGCCACAGCGAGGT– 3’ (reverse); 18S ribosome RNA primers were 5’ – 
TCGCTCCACCAACTAAGAAC – 3’ (forward) and 5’ – GAGGTTCGAAGACGATCAGA – 3’ (reverse). 
 
In vivo studies.  
   All animal experiments were done under strict adherence with Kansas State University Institutional 
Animal Care and Use Committee protocols. Wild-type female C57BL/6 mice obtained from the Jackson 
Laboratory were housed in a clean facility and held for 10 days to acclimatize. Experimental design I: 
LLC cells were seeded at 30000 cells per well in a 24-well plate and incubated 24 hrs in 10% FBS-
containing medium.  Medium was then changed to medium containing either the dTAT/pLUC (1ug of 
luciferase pDNA/well) or blank dTAT and incubated for 5 hrs.  After changing the media back to NP-free, 
10% FBS-containing media, cells were further incubated.  Five days after treatment, 100, 1000, or 10000 
cells were subcutaneously injected into the backs of the mice.  At various time points up to 1 week, 
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animals were imaged with a Caliper IVIS Lumina II biophotonic imager. Images were collected using a 6 
min exposure time.   
   In Experimental design II and III, each mouse was injected via the tail vein with 2 x 106 LLC cells 
suspended in 200 µl of PBS.  Experimental design II: Seven days after LLC cell injection, these mice 
were injected intratracheally using an intratracheal sprayer (Penn-Century Inc.) with 50µl of PBS (n=12) 
or 50µl of dTAT/pLUC (containing 0.7 g pDNA, n=12). On days 3, 7, 10, and 14 after intratracheal 
administration of the dTAT/pLUC, mice were sacrificed, and lungs were dissected for histological 
analysis of tumor multiplicity and size.  In addition, luciferase expression in the lung was analyzed 
immunohistochemically.  Experimental design III: On day 7 after LLC injection, these mice were 
intratracheally treated using the sprayer with 50µl of PBS (n=6), dTAT alone (n=5), dTAT/pAT2R (n=5), 
or dTAT/pTRAIL (n=5).  After sacrifice on day 15 after LLC inoculation,  lungs were fixed in 10% 
buffered formalin and used for histological and immunohistochemical analysis.  
 
Histological analysis 
 Fixed lung tissues were sectioned at 4 µm and stained with hematoxylin and eosin (H&E) for 
histological examination.  Quantitative evaluation of tumor nodules in the lungs was performed as 
previously described (38).  
 
Immunohistochemistry for luciferase, Ki-67, and AT2R in the tumor nodules 
 After deparaffinization and rehydration of the tissue sections, immunohistochemistry was carried out 
with antibodies to luciferase (1:1000, Novus Biologicals), Ki-67 (1:100, Abcam) and AT2R (1:100, 
Abcam), followed by incubation with biotin-conjugated antibodies against goat IgG or rabbit IgG (1:50, 
Vector Laboratories), reacted with the avidin-biotin peroxidase complex reagent (Vector Laboratories), 
visualized with 3, 3’-diaminobenzodine tetrahydrochloride (Sigma). To determine the Ki-67 labeling 
(proliferative) index, 10 nodules were selected randomly by light microscopy, and the number of Ki-67 
positive cells in each area was counted. The index was assessed as the percentage of Ki-67-positive 
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cells/tumor cells. 
 
TUNEL assay 
 TUNEL assay was carried out using the DeadEndTM colorimetric TUNEL system (Promega) as 
previously described (38). The fold change was calculated by dividing the percentage of TUNEL-positive 
tumor cells in the treated tumors by those in untreated tumors. 
 
Statistical analysis 
   All data are reported as mean ± SE.  Statistical significance was assessed by one-way ANOVA. Group 
comparisons were deemed significant for 2-tailed P values below 0.05. 
 
Results  
dTAT/pLUC NP caused efficient gene transfection with low cytotoxicity in vitro 
    In studies reported here, dTAT and pLUC complexes were thoroughly mixed by pipetting, and CaCl2 
was added to decrease the NP size through "soft" crosslinks of dTAT and pDNA (26). Here, the reduction 
in the size of dTAT/pLUC NP likely led to some of the noted increase in transfection. A CaCl2 
concentration of 69.2 mM consistently produced small (75-110 nm) and stable dTAT NP with a single 
particle population (polydispersity < 0.21).  
To investigate whether the dTAT affected the viability of LLC cells, the effect of free dTAT peptide or 
branched PEI (25 kDa) was analyzed by using a membrane translocalization signal (MTS) assay. LLC 
cells were incubated with up to 10 mg/mL of dTAT or PEI for ~24 hrs. Cytotoxicity profiles of dTAT 
peptides showed moderate cytotoxicity (IC50 ~4075 µg/mL, Fig. 1A), whereas branched PEI was strongly 
cytotoxic (IC50 ~28 µg/mL). Although the cell viability of LLC, A549, and BEAS-2B was slightly 
decreased by treatment with dTAT alone solution (1.86 or 3.72 g/mL) at days 3 and 5, there was no 
statistically significant difference among the groups (Supplemental Fig. 1).  
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   Luciferase gene expression was measured 48 h after transfection in order to study the ability of dTAT 
NP to transfect LLC cells (Fig. 1B).  Different N/P ratios of the dTAT or branched PEI (N/P 10) NP were 
studied using different concentrations of CaCl2 (0, 17.3, 34.6, and 69.2 mM) as a condensing agent after 
NP formation. Most dTAT NP showed a high level of gene expression at and above 34.6 mM of added 
CaCl2 for the various N/P ratios when compared to branched PEI, which had excellent transfection 
efficiency only in the absence of CaCl2. The study revealed that the highest transfection efficiency by 
dTAT was achieved at 69.2 mM CaCl2 and an N/P ratio of 33. It is important to note that gene expression 
was not detectable for dTAT/pLUC at CaCl2 levels up to 17.3 mM.  
dTAT-based AT2R gene transfection attenuated growth of lung cancer cells in vitro 
 To examine agents that effectively stabilize dTAT/pDNA NP and cause effective transfection, 
dTAT/pAT2R solution was mixed with either glucose, KCl, or NaCl solution prior to condensing 
complexes with CaCl2, and the efficacy of AT2R expression and cell viability was evaluated. Real-time 
PCR revealed that all of the agents caused effective DNA transfection at 2 µg dTAT/pAT2R per well (Fig. 
2A).  As shown in Fig. 2B, dTAT/pAT2R transfection significantly attenuated viability of LLC cells 
compared with dTAT alone.  Among the agents mixed with the dTAT/pAT2R solution, the glucose-
stabilized dTAT/pAT2R decreased cell viability most effectively, while treatment using dTAT alone 
slightly inhibited tumor cell growth (Fig. 2B). Incubation of LLC cells with the solution containing 
glucose, NaCl, or KCl alone without dTAT or pDNA had no adverse effect on cell viability (Supplemental 
Fig. 2).  Taken together, these results suggest that glucose was the most effective agent for dTAT/pDNA 
NP transfection, but by itself had no effect on tumor growth in vitro.  
 
In vivo imaging easily detects dTAT/pLUC NP transfected lung carcinoma cells in mice 
 Since the magnitude of gene expression is one key to successful gene therapy, gene expression was 
evaluated using an in vivo imaging system after dTAT/pLUC transfected LLC cells were transplanted into 
the backs of mice. In this experiment, luciferase expression was detected by in vivo imaging 24h after 
transplantation with a minimum number of 100 luciferase transfected cells. Luciferase expression by 
dTAT/pLUC was easily detectable for at least 7 days after transplantation when over 1000 luciferase 
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transfected cells were transplanted (Fig. 3). These results clearly indicate that dTAT NP-based gene 
transfection would be detectable for an in vivo mouse study.  
 
Administration of dTAT/pLUC NP via intratracheal spray caused luciferase expression 
preferentially in lung tumor cells  
    The effectiveness of intratracheally administered dTAT/pLUC NP, the luciferase expression sites, and 
the effect on tumor growth were quantitatively determined using LLC lung tumor bearing mice. 
Immunohistochemical detection of luciferase expression in the lung indicated that the primary expression 
sites are tumor cells and bronchioloalveolar epithelium (Fig. 4A). Strong luciferase expression was 
detected at 3 days after the intratracheal spray of dTAT/pLUC; this expression lasted until 14 days after 
the spray without losing much intensity, indicating that dTAT NP-based gene transfection is effective in 
vivo.  In addition, this dTAT/pLUC transfection via intratracheal spray did not show any effects on tumor 
growth (Fig.4B). Histological examination of tumors in H&E stained sections showed a large number of 
LLC tumor nodules in mouse lungs treated with either dTAT/pLUC or PBS.  The average number of 
tumors per view and the size of the tumors in both groups were not significantly different between the two 
groups (Fig. 4B).  
 
Administration of dTAT/pAT2R or pTRAIL NP via intratracheal spray caused significant growth 
attenuation of lung tumors 
    Since dTAT NP-based in vivo pDNA transfection was very effective and intratracheal spray was shown 
to deliver the dTAT/pLUC into the lung tumors effectively, the effect of dTAT NP-based in vivo 
transfection of endogenous apoptosis inducer genes, AT2R and TRAIL, was examined using orthotopic 
LLC lung tumor bearing mice. In this study, LLC cells (2 x 106) were inoculated via the tail vein. One 
week after cancer cell inoculation, during which time a preliminary study revealed that LLC grafts had 
started growing as microtumors, dTAT/pAT2R or dTAT/pTRAIL (1 µg DNA/50 µl solution) was sprayed 
once intratracheally. These treatments significantly decreased lung tumor prevalence as compared to PBS 
or dTAT/pLUC treated mice (Fig. 5A). The dTAT/pAT2R and pTRAIL also significantly decreased the 
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macroscopic lung tumor multiplicity (Fig. 5A).  Histological examination of tumors in H&E stained 
sections clearly showed a large number and size of LLC tumor nodules in mouse lungs treated with PBS, 
whereas only a small number of tumors were detected in dTAT/pAT2R treated mouse lungs (Fig. 5B-D). 
As expected, dTAT/pTRAIL attenuated both tumor size and the number of tumors significantly (Fig. 5).  
Interestingly, administering dTAT alone also attenuated tumor multiplicity and decreased tumor size (Fig. 
5C).  The AT2R expression site in the lung was determined immunohistochemically. As shown in Fig. 6, 
an intense immunoreactivity for AT2R was observed in the tumor cells in the dTAT/pAT2R treated group, 
but not in other groups (Fig. 6).  These microscopic observations suggested that an intratracheal 
dTAT/pAT2R spray significantly attenuated lung tumor growth by expressing AT2R in the tumor cells. 
Accordingly, these data support the assertion that intratracheal spray of dTAT/pAT2R is an effective 
modality for targeted lung cancer gene therapy.  
 
Determination of cell proliferation and apoptotic index in the tumors 
     To evaluate the effect of the treatments on the proliferative and apoptotic activities of tumor cells, 
numbers of Ki-67 and TUNEL positive cells in tumor tissues were determined.  Immunohistochemical 
analysis revealed that while the number of Ki-67 positive cells was slightly decreased in the dTAT/pAT2R 
or pTRAIL treated tumors, this difference was not significant (Fig. 7A and B).  In contrast, both 
dTAT/pAT2R and dTAT/pTRAIL increased apoptosis. The TUNEL positive cells were significantly 
increased in tumors of mice treated with dTAT/pAT2R and pTRAIL relative to those treated with PBS or 
dTAT (Fig. 7A and C). Treatment with dTAT alone did not significantly alter either cell proliferation or 
apoptosis. These results indicate that treatment with dTAT/pAT2R increased apoptosis of tumor cells and 
thus decreased tumor multiplicity and the tumor size.  
 
Discussion  
   The primary objectives of this study were to examine the efficacy of dTAT as a vector, to determine 
whether pDNA can be distributed to lung tumor cells and cause robust expression, and to evaluate the 
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effectiveness of dTAT NP-based delivery of AT2R or TRAIL pDNA, since AT2R or TRAIL over-
expression is known to attenuate tumor cell growth (34, 36, 37).  In addition, efficiency of intratracheal 
spray of dTAT/pDNA was evaluated utilizing luciferase, AT2R, and TRAIL pDNA. Results indicated that 
a bolus intratracheal spray of dTAT/pDNA caused robust gene expression, primarily in lung tumor cells. 
Expression of AT2R and TRAIL significantly attenuated tumor growth. Therefore, the present study 
introduces an effective in vivo gene delivery system using a cationic peptide, dTAT, for lung cancer 
therapy.   
   The first study indicated that dTAT NP-based transfection was comparable to PEI polyplexes (Fig. 1A). 
Our data indicate that under the conditions tested, dTAT did not show any practical acute cytotoxicity in 
vitro until nearly 5 mg/mL concentration for 24h, whereas PEI showed strong cytotoxicity at much lower 
concentrations (Fig. 1A). Evaluation of the cytotoxicity of dTAT alone using other cell types, such as 
human lung bronchial epithelial cells and human lung adenocarcinoma cells, also revealed similar low 
cytotoxicity (Supplemental Fig. 1).  Glucose or salt solution addition also did not affect viability in these 
other cell types (Supplemental Fig. 2). The low cytotoxicity was also shown in vivo after intratracheal 
application, in which all mice receiving dTAT alone or dTAT/pDNA survived during the experimental 
period and did not show any histologically detectable abnormality or acute inflammatory reaction (data 
not shown).  The low cytotoxicity of the dTAT peptide is in agreement with previous reports of TAT and 
other similar cell penetrating peptides (26, 39). Furthermore, our recent dTAT dose escalation toxicity 
study in mice with IV administration (39) suggests that this dTAT NP-based delivery system is minimally 
toxic. Accordingly, it is concluded that dTAT NP potentially represent an efficient and safe gene 
transfection vector, worthy of further in vivo studies.  
   The second study clarified that addition of either glucose, KCl, or NaCl to the dTAT/pDNA mixture 
caused equally effective DNA transfection, but addition of glucose caused the most significant attenuation 
of cell growth (Fig. 2). Although the first experiment clearly indicated that dTAT alone treatment was 
significantly less cytotoxic than PEI alone, treating cells with dTAT for two days attenuated cell viability 
(Fig. 2B).  Growth inhibition by treatment with dTAT alone is consistent with the report that the TAT 
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peptide itself can induce cell death (40).  The present study clearly indicated that the cell growth 
attenuation effect of dTAT is amplified when the dTAT NP is prepared with plasmids encoding an 
apoptosis inducer gene such as AT2R, suggesting that dTAT NP can effectively transfect genes in tumor 
cells and induce tumor cell death. 
   Gene therapy-dependent tumor growth inhibition requires sustained and robust transgene expression in 
order to be effective (26).  Accordingly, the intensity and duration of gene expression by dTAT NP 
transfection were determined by in vivo imaging after transplanting tumor cells transfected in vitro with 
dTAT/pLUC. Luciferase expression was detectable at days 1 and 3 after transplantation of only 100 
dTAT/pLUC-transfected cells. Luciferase expression was detectable for a week after the injection of 1000 
cells or more (Fig. 3).  These results indicated that dTAT/pDNA caused efficient transfection both in vitro 
and in vivo, and the duration of the strong expression is significantly long to prompt further study.   
   To examine the in vivo gene transfection efficiency of dTAT NP, the expression of luciferase in the lung 
was monitored immunohistochemically for 14 days after administering dTAT/pLUC via intratracheal 
spray in LLC tumor bearing mice. A single spray of dTAT/pLUC caused robust luciferase expression, 
primarily in the tumor cells and bronchial epithelium, for at least 14 days (Fig. 4A). These studies proved 
that dTAT NP cause long-lasting, robust gene expression in vivo. Hence, the current study suggested that 
gene transfection using dTAT NP was an effective strategy for in vivo gene therapy and is potentially 
selective for rapidly dividing lung cancer cells.   
   In the next study, delivery of the endogenous apoptosis inducer gene AT2R was examined using LLC 
tumor bearing mice.  pTRAIL was used as a positive control.  As expected, dTAT/pTRAIL attenuated 
tumor growth macroscopically and microscopically by inducing apoptosis (Figs. 5 and 7), indicating that 
dTAT NP gene transfection was effective.  In the dTAT/pAT2R treatment group, expression of AT2R was 
detected primarily in the tumor cells, which apparently led to the attenuation of the tumor growth. The 
degree of cell proliferation and apoptosis in the tumors suggested that bolus intratracheal spray of 
dTAT/pAT2R probably lowered tumor burden by inducing apoptosis of tumor cells rather than by 
attenuating cell proliferation (Fig. 7). These results are consistent with previous reports that AT2R is a 
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strong apoptosis inducer, attenuating growth of various cell types (41-43) including human lung cancer 
cells (37). Accordingly, induction of AT2R over-expression is a potential treatment scheme for lung 
cancer.  
   A single intratracheal spray of dTAT alone also attenuated tumor growth significantly (Fig. 5) as 
compared to the PBS controls. In support of this result, it has been shown that HIV-TAT peptide can 
directly attenuate growth of polyamine deprived cancer cells (40). Therefore, tumor growth attenuation in 
the lungs of LLC graft-bearing mice by dTAT alone may partly be caused by the direct tumoricidal effect 
of dTAT on the tumor cells. However, all mice receiving dTAT alone survived until sacrificed and showed 
no abnormal clinical signs or histological abnormalities in the normal areas of the lung. These results 
suggest that the dTAT-dependent cell growth attenuation appears to be limited to the tumor cells. As an 
alternative explanation, the dTAT peptide-dependent tumor attenuation may also be caused by a 
secondary effect of the dTAT peptide on the tumor microenvironment.  This speculation may be supported 
by the immunohistochemical observations that dTAT NP-dependent luciferase or AT2R expression was 
recognized in the alveolar epithelium (Figs. 4 and 6) and alveolar macrophages (data not shown).  This 
observation suggests that dTAT peptides are taken up by various types of cells in the lung, although gene 
expression levels are weaker than those in tumor cells. Since the tumor microenvironment is an important 
factor for tumor growth regulation (44-46), it is possible that dTAT modulates thetumor 
microenvironment toward conditions less favorable to tumor growth. Although further studies are 
required to better understand the effect of dTAT on tumor growth, this dTAT-dependent tumor suppression 
may be a beneficial adjuvant property of these therapeutic nanoparticles. 
   In conclusion, although further studies are required to substantiate the in vivo safety of dTAT NP by 
formal multi-species toxicity and pharmacokinetic studies, our data indicate that dTAT NP could be a safe 
and effective in vivo gene transfection tool. The present study provides clear evidence that intratracheal 
administration of dTAT NP-based therapeutic gene delivery causes strong gene expression preferentially 
in tumor cells.  A bolus intratracheal administration of dTAT/pAT2R or pTRAIL NP significantly 
attenuated the growth of fast growing Lewis lung carcinoma tumors, suggesting that dTAT NP-based gene 
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therapy is effective and useful for lung cancer treatment. AT2R is a potentially useful gene for lung cancer 
therapy.  
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Figure 1. A, Cytotoxicity profiles of PEI and dTAT. Cell viability is expressed as a function of 
polymer concentration. Results are presented as mean ± SD (n = 3). p < 0.05, as compared to 
the cytoxicity of the dTAT group at the same concentration. B, The transfection efficiency of PEI 
and dTAT NP with different concentrations of added CaCl2. Results are presented as mean ± SD 
(n = 3). 
   
 
 
 
 
 
 
 
 
21 
 
Figure 2. Addition of glucose to the dTAT/pDNA NP caused cell growth attenuation most 
efficiently. (A) Real time PCR confirmed either glucose, KCl or NaCl is effective in dTAT/pAT2R 
transfection (1 or 2g pAT2R per well of the 24 well plate. AT2R mRNA expression was 
determined two days after the treatment. Bar graphs indicate the average of two independent 
triplicate determinations. (B)  The dTAT/pAT2R including glucose showed the strongest growth 
attenuation effect. In this study, each well contains 0.25 or 0.5 g of pAT2R in the 96 well plate. 
Cell viability was determined two days after the treatment. Bar graphs indicate the average of 
two independent triplicate determinations. *, p < 0.05, as compared to the level of dTAT alone 
group. ** p < 0.05, as compared to the level of glucose group.  *** p < 0.05, as compared to the 
level of PBS-control group.  
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Figure 3.  Bioluminescence IVIS images of firefly luciferase-expressing LLC cells transplanted 
subcutaneously in the backs of the mice.  LLC cells were transfected with either dTAT/pLUC or 
dTAT NP alone in vitro and various cell numbers were transplanted into the backs of C57BL/6 
mice as indicated in the figure.  
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Figure 4. Determination of luciferase expression in LLC tumor-bearing lung treated with 
dTAT/pLUC via intratracheal spray.  A, Specific localization of luciferase expression in LLC 
tumor-bearing mouse lung by immunohistochemistry.. The tumor cells were immunostained 
with luciferase antibody in the LLC lung nodule at various time points up to 2 weeks after the 
administration of dTAT/pLUC.   B, the average tumor numbers in three view areas at 40x  and 
tumor size of ten tumor nodules in each treatment group at 100x were expressed in the bar 
graph.  
  
A 
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Figure 5. Macroscopic and microscopic analysis of LLC tumors in C57 BL/6 mouse lungs. . A and 
B, macroscopic and microscopic views of the lung from a dTAT alone, dTAT/pAT2R or 
dTAT/pTRAIL treated mouse. Scale bars in macroscopic figures indicate 5mm.  C and D, the 
average tumor numbers in 3 view areas at 40xand tumor size of 10 tumor areas at 100x in each 
treatment group were expressed in the bar graphs, respectively.  * p < 0.05, as compared to the 
level of PBS control. p < 0.05, as compared to the level of dTAT alone group. 
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Figure 6. Specific localization of AT2R in LLC tumor-bearing mouse lung. Immunohistochemical 
image of the lung from a dTAT/pAT2R treated mouse shows AT2R expression in the tumor cells. 
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Figure 7. Immunohistochemical analysis of cell division (A and B) and apoptosis (A and C) in 
LLC graft tumors in C57 BL/6 mouse lungs treated with either PBS, dTAT, dTAT/pAT2R or 
dTAT/pTRAIL. A, microscopic images of immunohistochemistry for Ki-67 (top 4 panels) at 100x 
and TUNEL assay  (bottom 4 panels) at 100x. B, treatment with dTAT/pAT2R or pTRAIL had 
no significant effect on  proliferation of the tumor cells. C, the TUNEL positive cells were significantly 
increased in tumors of mice treated with dTAT/pAT2R and pTRAIL * p < 0.05 as compared to the level of 
PBS-treated control. p < 0.05, as compared to the level of dTAT alone group. 
    
                     
 
 
 
